Claims
- 1. A linear 9 to 11 mer peptide selected from the group consisting of:
- LNFGQYLWYT (SEQ ID NO: 1),
- LCFGCYLWYT (SEQ ID NO: 2),
- LNFGCYLWCT (SEQ ID NO: 3),
- LNFGQYLnAYT (SEQ ID NO: 4),
- LNFdSQYLWYT (SEQ ID NO: 5),
- LCFGCYLWY (SEQ ID NO: 6),
- LNFdSQYLnAYT (SEQ ID NO: 7),
- LNFGdCYLWCT (SEQ ID NO: 8),
- LCFdSCYLWYT (SEQ ID NO: 9),
- LCFdSCYLnAYT (SEQ ID NO: 10),
- LNFdSCYLWCT (SEQ ID NO: 11),
- or an active 9 to 11 mer analog thereof, wherein the sequence of said active analog differs from the sequence of said peptide by 1 to 3 amino acid residues, and wherein said active analog exhibits a K.sub.d .ltoreq.250 nM with huPAR.
- 2. A method for treating huPA-mediated disorders, said method comprising: administering to a subject an effective amount of a linear 9-11 mer peptide selected from the group consisting of:
- LNFGQYLWYT (SEQ ID NO: 1),
- LCFGCYLWYT (SEQ ID NO: 2),
- LNFGCYLWCT (SEQ ID NO: 3),
- LNFGQYLnAYT (SEQ ID NO: 4),
- LNFdSQYLWYT (SEQ ID NO: 5),
- LCFGCYLWY (SEQ ID NO: 6),
- LNFdSQYLnAYT (SEQ ID NO: 7),
- LNFGdCYLWCT (SEQ ID NO: 8),
- LCFdSCYLWYT (SEQ ID NO: 9),
- LCFdSCYLnAYT (SEQ ID NO: 10),
- LNFdSCYLWCT (SEQ ID NO: 11),
- or an active 9 to 11 mer analog thereof, wherein the sequence of said active analog differs from the sequence of said peptide by 1 to 3 amino acid residues, and wherein said active analog exhibits a K.sub.d .ltoreq.250 nM with huPAR.
- 3. The method of claim 2, wherein said huPA-mediated disorder is selected from the group consisting of metastasis, inappropriate angiogenesis, and chronic inflammation.
- 4. The method of claim 2, wherein said huPA-mediated disorder is selected from the group consisting of Kaposi's sarcoma, diabetic retinopathy, and rheumatoid arthritis.
- 5. The method of claim 2, wherein said peptide is administered by instillation in the eye.
- 6. A composition comprising:
- a pharmaceutically acceptable excipient, and
- an effective amount of a linear 9-11 mer peptide selected from the group consisting of:
- LNFGQYLWYT (SEQ ID NO: 1),
- LCFGCYLWYT (SEQ ID NO: 2),
- LNFGCYLWCT (SEQ ID NO: 3),
- LNFGQYLnAYT (SEQ ID NO: 4),
- LNFdSQYLWYT (SEQ ID NO: 5),
- LCFGCYLWY (SEQ ID NO: 6),
- LNFdSQYLnAYT (SEQ ID NO: 7),
- LNFGdCYLWCT (SEQ ID NO: 8),
- LCFdSCYLWYT (SEQ ID NO: 9),
- LCFdSCYLnAYT (SEQ ID NO: 10),
- LNFdSCYLWCT (SEQ ID NO: 11),
- or an active 9 to 11 mer analog thereof, wherein the sequence of said active analog differs from the sequence of said peptide by 1 to 3 amino acid residues, and wherein said active analog exhibits a K.sub.d .ltoreq.250 nM with huPAR.
Parent Case Info
This application is a continuation-in-part of International Application No. PCT/US96/12044, filed Jul. 19, 1996 and continuation-in-part of U.S. patent application Ser. No. 08/509,208 filed Jul. 31, 1995.
US Referenced Citations (2)
Number |
Name |
Date |
Kind |
5340833 |
Bridges et al. |
Aug 1994 |
|
5656726 |
Rosenberg et al. |
Aug 1997 |
|
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
PCTUS9612044 |
Jul 1996 |
|